ArticleJournal of ovarian research2022
Efficacy of IOTA simple rules, O-RADS, and CA125 to distinguish benign and malignant adnexal masses.
Article in Journal of ovarian research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Have Iota Simple Rules the Same Diagnostic Performance When Used by Nonexpert Examiners as Compared to Expert Examiners? Systematic Review and Meta-Analisis.Journal of clinical ultrasound : JCU · 2026Pooled it
- Comparison of the Diagnostic Performance of Ovarian Adnexal Reporting Data System (O-RADS) With IOTA Simple Rules and ADNEX Model for Classifying Adnexal Masses: A Head-To-Head Meta-Analysis.Journal of clinical ultrasound : JCU · 2025Pooled it
- Comparison of O-RADS with the ADNEX model and IOTA SR for risk stratification of adnexal lesions: a systematic review and meta-analysis.Frontiers in oncology · 2024Pooled it
- Exploring the value of the ovarian-adnexal reporting and data system combined with tumor markers in the differential diagnosis of benign and malignant ovarian-adnexal tumors.Molecular and clinical oncology · 2026Article
- Diagnostic performance of deep learning models on ultrasound images for distinguishing benign from malignant ovarian cysts.Journal of ovarian research · 2026Article
- Diagnostic performance and interobserver agreement of O-RADS US v2022 and its combination with serum biomarkers in surgically treated epithelial ovarian-adnexal masses.Frontiers in medicine · 2026Article
- Diagnostic performance of serum CA-125 and ultrasonography in ovarian tumour differentiation.Bioinformation · 2026Article
- Contrast-enhanced ultrasound and Ovarian-Adnexal Reporting and Data System ultrasound classification for risk assessment of ovarian and adnexal lesions: a systematic review and meta-analysis.Quantitative imaging in medicine and surgery · 2026Article
- Clinical and ultrasound characteristics of primary fallopian tube carcinoma: a single-institution retrospective study of 280 cases.Archives of gynecology and obstetrics · 2025Article
- Review
- Can transabdominal shear wave elastography play a role in solving the dilemma of complex cystic and solid ovarian tumors by ultrasound?Journal of ultrasound · 2025Article
- CA125 as a Potential Biomarker in Non-Malignant Serous Effusions: Diagnostic and Prognostic Considerations.Journal of clinical medicine · 2025Review
- Accurate prediction of benign and malignant adnexal tumors in surgical resection and conservative treatment: construction and external validation of a diagnostic model based on CEUS, HE4, and O-RADS US v2022 evaluation.Journal of ovarian research · 2025Article
- A nomogram combining clinical features, O-RADS US, and radiomics based on ultrasound imaging for diagnosing ovarian cancer.Scientific reports · 2025Article
- Diagnostic performances of the Ovarian Adnexal Reporting and Data System, the Risk of Ovarian Malignancy Algorithm, and the Copenhagen Index in the preoperative prediction of ovarian cancer: a prospective cohort study.Journal of gynecologic oncology · 2025Article
- Sensitive and Cost-Effective Tools in the Detection of Ovarian Cancer Biomarkers.Analytical science advances · 2024Article
- Article
- Clinical value of ACR O-RADS combined with CA125 in the risk stratification of adnexal masses.Frontiers in oncology · 2024Article
- Comparison of International Ovarian Tumor Analysis ADNEX model and Ovarian-Adnexal Reporting and Data System with final histological diagnosis in adnexal masses: a retrospective study.Obstetrics & gynecology science · 2024Article
- The diagnostic performance of International Ovarian Tumor Analysis: Simple Rules for diagnosing ovarian tumors-a systematic review and meta-analysis.Frontiers in oncology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectiveOvarian cancer is the most deadly deadliest gynecological tumor in the female reproductive system. Therefore, the present study sought to determine the diagnostic performance of International Ovarian Tumor Analysis Simple Rules (IOTA SR), the Ovarian-Adnexal Reporting and Data System (O-RADS), and Cancer Antigen 125 (CA125) in discriminating benign and malignant ovarian tumors. The study also assessed whether a combination of the two ultrasound categories systems and CA125 can improve the diagnostic performance.
methodsA total of 453 patients diagnosed with ovarian tumors were retrospectively enrolled from Fujian Cancer Hospital between January 2017 and September 2020. The data collected from patients included age, maximum lesion diameter, location, histopathology, levels of CA125, and detailed ultrasound reports. Additionally, all ultrasound images were independently assessed by two ultrasound physicians with more than 5 years of experience in the field, according to the IOTA simple rules and O-RADS guidelines. Furthermore, the area under the curve (AUC), sensitivity, and specificity of the above mentioned predictors were calculated using the receiver operating characteristic curve.
resultsOut of the 453 patients, 184 had benign lesions, while 269 had malignant ovarian tumors. In addition, the AUCs of IOTA SR, O-RADS, and CA125 in the overall population were 0.831, 0.804, and 0.812, respectively, and the sensitivities of IOTA SR, O-RADS, and CA125 were 94.42, 94.42, and 80.30%, respectively. On the other hand, the AUCs of IOTA SR combined with CA125, O-RADS combined with CA125, and IOTA SR plus O-RADS combined with CA125 were 0.900, 0.891, and 0.909, respectively. The findings also showed that the AUCs of a combination of the three approaches were significantly higher than those of individual strategies (p<0.05) but not significantly higher than the AUC of a combination of two methods (p>0.05).
conclusionThe findings showed that a combination of IOTA SR or O-RADS in combination with CA125 may improve the ability to distinguish benign from malignant ovarian tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.